These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 19199782)

  • 41. Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors.
    Eshleman AJ; Nagarajan S; Wolfrum KM; Reed JF; Nilsen A; Torralva R; Janowsky A
    Biochem Pharmacol; 2020 Dec; 182():114293. PubMed ID: 33091380
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinity and function.
    Yuan Y; Elbegdorj O; Beletskaya IO; Selley DE; Zhang Y
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5045-8. PubMed ID: 23948248
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
    Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
    J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a micro-agonist delta-antagonist and delta-inverse agonists.
    Cheng K; Kim IJ; Lee MJ; Adah SA; Raymond TJ; Bilsky EJ; Aceto MD; May EL; Harris LS; Coop A; Dersch CM; Rothman RB; Jacobson AE; Rice KC
    Org Biomol Chem; 2007 Apr; 5(8):1177-1190. PubMed ID: 17406716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
    Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
    J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.
    Zhang B; Zhang T; Sromek AW; Scrimale T; Bidlack JM; Neumeyer JL
    Bioorg Med Chem; 2011 May; 19(9):2808-16. PubMed ID: 21482470
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacological profiles of selective non-peptidic delta opioid receptor ligands.
    Chaturvedi K; Jiang X; Christoffers KH; Chinen N; Bandari P; Raveglia LF; Ronzoni S; Dondio G; Howells RD
    Brain Res Mol Brain Res; 2000 Sep; 80(2):166-76. PubMed ID: 11038249
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder.
    Zheng Y; Obeng S; Reinecke BA; Chen C; Phansalkar PS; Walentiny DM; Gerk PM; Liu-Chen LY; Selley DE; Beardsley PM; Zhang Y
    Eur J Pharmacol; 2019 Dec; 865():172812. PubMed ID: 31743739
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.
    Wang D; Raehal KM; Bilsky EJ; Sadée W
    J Neurochem; 2001 Jun; 77(6):1590-600. PubMed ID: 11413242
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors.
    Fulton BS; Knapp BL; Bidlack JM; Neumeyer JL
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1507-9. PubMed ID: 20144870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and evaluation of novel opioid ligands with a C-homomorphinan skeleton.
    Ishikawa K; Mochizuki Y; Hirayama S; Nemoto T; Nagai K; Itoh K; Fujii H
    Bioorg Med Chem; 2016 May; 24(10):2199-205. PubMed ID: 27079125
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
    Metzger TG; Paterlini MG; Ferguson DM; Portoghese PS
    J Med Chem; 2001 Mar; 44(6):857-62. PubMed ID: 11300867
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.
    Provencher BA; Sromek AW; Li W; Russell S; Chartoff E; Knapp BI; Bidlack JM; Neumeyer JL
    J Med Chem; 2013 Nov; 56(21):8872-8. PubMed ID: 24107104
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties.
    Mathews JL; Fulton BS; Negus SS; Neumeyer JL; Bidlack JM
    Neurochem Res; 2008 Oct; 33(10):2142-50. PubMed ID: 18528756
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
    Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
    J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Pharmacological Heterogeneity of Nepenthone Analogs in Conferring Highly Selective and Potent κ-Opioid Agonistic Activities.
    Li W; Long JD; Qian YY; Long Y; Xu XJ; Wang YJ; Shen Q; Wang ZN; Yang XC; Xiao L; Sun HP; Xu YL; Chen YY; Xie Q; Wang YH; Shao LM; Liu JG; Qiu ZB; Fu W
    ACS Chem Neurosci; 2017 Apr; 8(4):766-776. PubMed ID: 28033462
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
    Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
    Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structure-Activity Relationship Studies of 6α- and 6β-Indolylacetamidonaltrexamine Derivatives as Bitopic Mu Opioid Receptor Modulators and Elaboration of the "Message-Address Concept" To Comprehend Their Functional Conversion.
    Obeng S; Wang H; Jali A; Stevens DL; Akbarali HI; Dewey WL; Selley DE; Zhang Y
    ACS Chem Neurosci; 2019 Mar; 10(3):1075-1090. PubMed ID: 30156823
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.
    Le Bourdonnec B; Goodman AJ; Graczyk TM; Belanger S; Seida PR; DeHaven RN; Dolle RE
    J Med Chem; 2006 Dec; 49(25):7290-306. PubMed ID: 17149859
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.
    Greiner E; Spetea M; Krassnig R; Schüllner F; Aceto M; Harris LS; Traynor JR; Woods JH; Coop A; Schmidhammer H
    J Med Chem; 2003 Apr; 46(9):1758-63. PubMed ID: 12699394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.